Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils
Journal Title
Scientific Reports
Publication Type
Journal Article
Abstract
Devil facial tumour disease (DFTD) is a transmissible cancer devastating the Tasmanian devil (Sarcophilus harrisii) population. The cancer cell is the 'infectious' agent transmitted as an allograft by biting. Animals usually die within a few months with no evidence of antibody or immune cell responses against the DFTD allograft. This lack of anti-tumour immunity is attributed to an absence of cell surface major histocompatibility complex (MHC)-I molecule expression. While the endangerment of the devil population precludes experimentation on large experimental groups, those examined in our study indicated that immunisation and immunotherapy with DFTD cells expressing surface MHC-I corresponded with effective anti-tumour responses. Tumour engraftment did not occur in one of the five immunised Tasmanian devils, and regression followed therapy of experimentally induced DFTD tumours in three Tasmanian devils. Regression correlated with immune cell infiltration and antibody responses against DFTD cells. These data support the concept that immunisation of devils with DFTD cancer cells can successfully induce humoral responses against DFTD and trigger immune-mediated regression of established tumours. Our findings support the feasibility of a protective DFTD vaccine and ultimately the preservation of the species.
Publisher
Springer Nature
WEHI Research Division(s)
Bioinformatics; Molecular Immunology; Cell Signalling And Cell Death
PubMed ID
28276463
Publisher's Version
https://doi.org/10.1038/srep43827
Open Access at Publisher's Site
https://www-nature-com/articles/srep4382
NHMRC Grants
NHMRC/1105754 NHMRC/1054925
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2017-04-12 10:42:26
Last Modified: 2017-04-12 12:07:10
An error has occurred. This application may no longer respond until reloaded. Reload 🗙